価格表

在庫・価格 : 2019年10月16日 11時43分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-LRRK2, Rabbit-Poly <Anti-Leucine-Rich Repeat Kinase 2>
データシート※最新のデータシートでない場合があります
NB300-268SS NOVノバス バイオロジカルス
Novus biologicals, LLC
0.025 ml ¥19,000
(未発注)
追加

在庫・価格 : 2019年10月16日 11時43分 現在

Anti-LRRK2, Rabbit-Poly <Anti-Leucine-Rich Repeat Kinase 2>

  • 商品コード:NB300-268SS
  • メーカー:NOV
  • 包装:0.025ml
  • 価格: ¥19,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Miklossy J et al. LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neuropathol. Exp. Neurol. 2006 Oct;65(10):953-63
Miklossy J et al
2006/01/01
PubMed
2 Melrose HL et al. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007 Jul;147(4):1047-58
Melrose HL et al
2007/01/01
Western Blot, Immunohistochemistry PubMed
3 Hakimi M et al. Parkinson''s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 2011 May;118(5):795-808
Hakimi M et al
2011/01/01
Species: Human, Mouse, Applications: WB PubMed
4 Alegre-Abarrategui J et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009 Nov;18(21):4022-34
Alegre-Abarrategui J et al
2009/01/01
Species: Human, Applications: ICC/IF, WB PubMed
5 Sekigawa A et al. Distinct mechanisms of axonal globule formation in mice expressing human wild type &#x3B1;-synuclein or dementia with Lewy bodies-linked P123H &#x3B2;-synuclein. Mol Brain 2012;5:34
Sekigawa A et al
2012/01/01
Species: Mouse, Applications: IHC-Fr PubMed
6 Venderova K et al. Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson''s disease. Hum. Mol. Genet. 2009 Nov;18(22):4390-404
Venderova K et al
2009/01/01
Species: Human, Applications: WB PubMed
7 Yao C et al. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson''s disease. Neurobiol. Dis. 2010 Oct;40(1):73-81
Yao C et al
2010/01/01
Species: C. elegans, Applications: IHC, ICC/IF, WB PubMed
8 Pandey N et al. Sequences Located within the N-Terminus of the PD-Linked LRRK2 Lead to Increased Aggregation and Attenuation of 6-Hydroxydopamine-Induced Cell Death. PLoS ONE 2012;7(9):e45149
Pandey N et al
2012/01/01
Species: Human, Applications: WB PubMed
9 Greggio E et al. Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J. Neurochem. 2007 Jul;102(1):93-102
Greggio E et al
2007/01/01
Species: Human, Applications: WB PubMed
10 Kamikawaji S et al. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation. Biochemistry 2013 Sep;52(35):6052-62
Kamikawaji S et al
2013/01/01
Species: Human, Applications: WB PubMed
11 Angeles DC et al. Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Hum. Mol. Genet. 2014 Jun;23(12):3157-65
Angeles DC et al
2014/01/01
Species: Human, Applications: WB PubMed
12 Marker DF et al. LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. J Neuroinflammation 2012;9:261
Marker DF et al
2012/01/01
Species: Mouse, Applications: ICC/IF PubMed
13 Liu Z et al. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 2011 Nov;12(11):1063-70
Liu Z et al
2011/01/01
Applications: PubMed
14 Saha S et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 2009 Jul;29(29):9210-8
Saha S et al
2009/01/01
Species: C. elegans, Applications: WB PubMed
15 Qing H et al. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem. Biophys. Res. Commun. 2009 Dec;390(4):1229-34
Qing H et al
2009/01/01
Species: Human, Applications: IHC, ICC/IF PubMed
16 Ito G et al. Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form. Biochem. J. 2012 Feb;441(3):987-94
Ito G et al
2012/01/01
PubMed
17 Hatano T et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet. 2007 Mar;16(6):678-90
Hatano T et al
2007/01/01
Species: Mouse, Applications: WB PubMed
18 Kamikawaji S et al. Identification of the autophosphorylation sites of LRRK2. Biochemistry 2009 Nov;48(46):10963-75
Kamikawaji S et al
2009/01/01
Species: Human, Moth, Applications: IP, WB PubMed
19 Chan SL et al. MAP1B rescues LRRK2 mutant-mediated cytotoxicity. Mol Brain 2014;7:29
Chan SL et al
2014/01/01
Species: Human, Applications: ICC/IF, WB PubMed
20 Santpere G et al. LRRK2 and neurodegeneration. Acta Neuropathol. 2009 Mar;117(3):227-46
Santpere G et al
2009/01/01
Species: Human, Applications: WB, ICC/IF PubMed
  • No.: 1
  • 文献情報:
    Miklossy J et al. LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neuropathol. Exp. Neurol. 2006 Oct;65(10):953-63
    Miklossy J et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Melrose HL et al. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007 Jul;147(4):1047-58
    Melrose HL et al
    2007/01/01
  • 備考:
    Western Blot, Immunohistochemistry
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Hakimi M et al. Parkinson''s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 2011 May;118(5):795-808
    Hakimi M et al
    2011/01/01
  • 備考:
    Species: Human, Mouse, Applications: WB
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Alegre-Abarrategui J et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009 Nov;18(21):4022-34
    Alegre-Abarrategui J et al
    2009/01/01
  • 備考:
    Species: Human, Applications: ICC/IF, WB
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Sekigawa A et al. Distinct mechanisms of axonal globule formation in mice expressing human wild type &#x3B1;-synuclein or dementia with Lewy bodies-linked P123H &#x3B2;-synuclein. Mol Brain 2012;5:34
    Sekigawa A et al
    2012/01/01
  • 備考:
    Species: Mouse, Applications: IHC-Fr
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Venderova K et al. Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson''s disease. Hum. Mol. Genet. 2009 Nov;18(22):4390-404
    Venderova K et al
    2009/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Yao C et al. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson''s disease. Neurobiol. Dis. 2010 Oct;40(1):73-81
    Yao C et al
    2010/01/01
  • 備考:
    Species: C. elegans, Applications: IHC, ICC/IF, WB
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Pandey N et al. Sequences Located within the N-Terminus of the PD-Linked LRRK2 Lead to Increased Aggregation and Attenuation of 6-Hydroxydopamine-Induced Cell Death. PLoS ONE 2012;7(9):e45149
    Pandey N et al
    2012/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Greggio E et al. Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J. Neurochem. 2007 Jul;102(1):93-102
    Greggio E et al
    2007/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Kamikawaji S et al. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation. Biochemistry 2013 Sep;52(35):6052-62
    Kamikawaji S et al
    2013/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Angeles DC et al. Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Hum. Mol. Genet. 2014 Jun;23(12):3157-65
    Angeles DC et al
    2014/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Marker DF et al. LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. J Neuroinflammation 2012;9:261
    Marker DF et al
    2012/01/01
  • 備考:
    Species: Mouse, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Liu Z et al. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 2011 Nov;12(11):1063-70
    Liu Z et al
    2011/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Saha S et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 2009 Jul;29(29):9210-8
    Saha S et al
    2009/01/01
  • 備考:
    Species: C. elegans, Applications: WB
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Qing H et al. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem. Biophys. Res. Commun. 2009 Dec;390(4):1229-34
    Qing H et al
    2009/01/01
  • 備考:
    Species: Human, Applications: IHC, ICC/IF
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Ito G et al. Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form. Biochem. J. 2012 Feb;441(3):987-94
    Ito G et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Hatano T et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet. 2007 Mar;16(6):678-90
    Hatano T et al
    2007/01/01
  • 備考:
    Species: Mouse, Applications: WB
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Kamikawaji S et al. Identification of the autophosphorylation sites of LRRK2. Biochemistry 2009 Nov;48(46):10963-75
    Kamikawaji S et al
    2009/01/01
  • 備考:
    Species: Human, Moth, Applications: IP, WB
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Chan SL et al. MAP1B rescues LRRK2 mutant-mediated cytotoxicity. Mol Brain 2014;7:29
    Chan SL et al
    2014/01/01
  • 備考:
    Species: Human, Applications: ICC/IF, WB
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Santpere G et al. LRRK2 and neurodegeneration. Acta Neuropathol. 2009 Mar;117(3):227-46
    Santpere G et al
    2009/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed